cancer is comparable to that of similarly staged colon and sigmoid cancers, 2 patients with locally advanced rectal cancer (LARC; T3-4 or node-positive LARC) experience a significantly higher local recurrence risk than their counterparts with colon
Search Results
Multidisciplinary Management of Locally Advanced Rectal Cancer: Neoadjuvant Approaches
Swaminathan Murugappan, William P. Harris, Christopher G. Willett, and Edward Lin
Optimal Neoadjuvant Strategies for Locally Advanced Rectal Cancer by Risk Assessment and Tumor Location
Anurag Saraf, Hannah J. Roberts, Jennifer Y. Wo, and Aparna R. Parikh
Although early-stage rectal cancer is primarily treated with surgery, locally advanced rectal cancer (LARC), defined here as T3–4 or N-positive disease, generally involves multimodality therapy with surgery, radiation therapy (RT), and
Updates in the Management of Locally Advanced Rectal Cancer
Presented by: Christopher G. Willett
the mesorectal fat along the posterior rectum. “Looking back to 2017, the treatments were pretty straightforward,” Dr. Willett remarked. Typically, patients with locally advanced rectal cancer were given preoperative chemoradiation (CRT) or short
Evolving Treatment Paradigm in the Treatment of Locally Advanced Rectal Cancer
Clayton A. Smith and Lisa A. Kachnic
Despite this improvement, patients with locally advanced rectal cancer (LARC; commonly defined as T3 or T4 primary or nodal metastases) still had unacceptably high risks of local and distant failure relative to those with early-stage disease. Therefore
Neoadjuvant Chemotherapy First, Followed by Chemoradiation and Then Surgery, in the Management of Locally Advanced Rectal Cancer
Andrea Cercek, Karyn A. Goodman, Carla Hajj, Emily Weisberger, Neil H. Segal, Diane L. Reidy-Lagunes, Zsofia K. Stadler, Abraham J. Wu, Martin R. Weiser, Philip B. Paty, Jose G. Guillem, Garrett M. Nash, Larissa K. Temple, Julio Garcia-Aguilar, and Leonard B. Saltz
Modern therapy for locally advanced rectal cancer (LARC), with the combination of preoperative chemoradiotherapy and improved surgical techniques, has led to significant improvements in local disease control. Distant recurrence rates now exceed
Early Postoperative Mortality Among Patients Aged 75 Years or Older With Stage II/III Rectal Cancer
Helmneh M. Sineshaw, K. Robin Yabroff, V. Liana Tsikitis, Ahmedin Jemal, and Timur Mitin
with locally advanced rectal cancer (LARC) in the United States using data from the National Cancer Database (NCDB). 8 Patients who received concurrent chemoradiation therapy without surgery had lower survival rates. 8 Others, however, used
Neoadjuvant Radiotherapy Use in Locally Advanced Rectal Cancer at NCCN Member Institutions
Marsha Reyngold, Joyce Niland, Anna ter Veer, Dana Milne, Tanios Bekaii-Saab, Steven J. Cohen, Lily Lai, Deborah Schrag, John M. Skibber, William Small Jr, Martin Weiser, Neal Wilkinson, and Karyn A. Goodman
Preoperative chemoradiation followed by surgical resection has been the standard of care in the management of locally advanced rectal cancer. Patients with T3-T4 or node-positive disease have a significant risk of both local and distant failure
Neoadjuvant Immunotherapy–Based Systemic Treatment in MMR-Deficient or MSI-High Rectal Cancer: Case Series
Rahel Demisse, Neha Damle, Edward Kim, Jun Gong, Marwan Fakih, Cathy Eng, Leslie Oesterich, Madison McKenny, Jingran Ji, James Liu, Ryan Louie, Kit Tam, Sepideh Gholami, Wissam Halabi, Arta Monjazeb, Farshid Dayyani, and May Cho
standard of care for locally advanced rectal cancer remains chemoradiation, systemic chemotherapy, and, commonly, surgical resection. For patients who are unable to undergo these therapeutic modalities or who do not to experience a response to them
Diagnosis and Management of Rectal Cancer in Patients Younger Than 50 Years: Rising Global Incidence and Unique Challenges
Daenielle Lang and Kristen K. Ciombor
negative predictive biomarker of response to anti-EGFR therapy. 20 Locally Advanced Disease Patients with locally advanced rectal cancer (LARC) are treated similarly to the EORC population when compared with the general population, but there are a
Multidisciplinary Management of Early-Stage Rectal Cancer
John G. Phillips, Theodore S. Hong, and David P. Ryan
that patients with locally advanced rectal cancer had better outcomes when both radiation and chemotherapy were used in the adjuvant setting, so-called combined modality therapy. 1 , 2 Subsequently, the Mayo/North Central Cancer Treatment Group (NCCTG
